E. S. Bagdasarova

E. S. Bagdasarova

Auto-generated profile, based on publicly available information

E. S. Bagdasarova

State Scientific Centre of the Russian Federation – Federal Medical Biophysical Centre n. a. A. I. Burnazyan

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2026 in Journal of Movement Disorders
Verified
Journal Article
Open access
PDF file
OTOybek Erkin ugli Turgunkhujaev
Oybek Erkin ugli Turgunkhujaev
EBElina Bagdasarova
Elina Bagdasarova
SLShen-Yang Lim
Shen-Yang Lim
Levodopa-Induced Oculogyric Crisis in Multiple System Atrophy

26 December 2025 in Medical alphabet
Verified
Journal Article
Closed access
EBEkaterina Bril
Ekaterina Bril
OZO. S. Zimnyakova
O. S. Zimnyakova
OTOybek Erkin ugli Turgunkhujaev
Oybek Erkin ugli Turgunkhujaev
EBE. S. Bagdasarova
E. S. Bagdasarova
IZI. A. Zdorovec
I. A. Zdorovec
Multisystem atrophy (MSA) is a sporadic progressive neurodegenerative disease that is manifested by a combination of autonomic and motor dysfunctions: parkinsonism, cerebellar ataxia, pyramidal syndrome, etc. Given the complexity of the diagnosis, the clinical polymorphism and the ignorance of neurologists about this disease, patients are often followed up by doctors of other profile or are observed with an incorrect diagnosis. There are two main MCA phenotypes – predominant cerebellar ataxia (MSA-C) and predominant parkinsonism (MSA-P), which are determined by the localization of the affected structures and the dominance of certain clinical symptoms. This article presents three clinical cases with different subtypes of MSA. Despite the difference in clinical manifestations, all patients was diagnosed with clinically established MSA. The features of the collection of complaints and anamnesis are described, the analysis of the neurological status and characteristic neuroimaging markers that can help in the differential diagnosis of this rare disease is carried out.

13 May 2026 in Medical alphabet
Verified
Journal Article
Closed access
EBEkaterina Bril
Ekaterina Bril
OZO. S. Zimnyakova
O. S. Zimnyakova
OTOybek Erkin ugli Turgunkhujaev
Oybek Erkin ugli Turgunkhujaev
EBE. S. Bagdasarova
E. S. Bagdasarova
IZI. A. Zdorovec
I. A. Zdorovec
Multiple system atrophy (MSA) is a rare, sporadically occurring neurodegenerative disease with a progressive course. MSA is characterized by a combination of autonomic dysfunction and motor disturbances, including parkinsonian syndrome, cerebellar ataxia, pyramidal symptoms, and other manifestations. Diagnosis of this disease is often challenging due to the diversity of clinical presentations and insufficient awareness among neurologists, which can lead to misdiagnosis or patients being monitored by specialists in other fields. Depending on the predominant symptoms and the localization of lesions in the central nervous system, two main clinical variants of MSA are distinguished: parkinsonian (MSA-P) and cerebellar (MSA-C). This article presents important current preclinical and clinical studies focused on slowing the progression of MSA, including drugs targeting pathological α-synuclein, as well as neuroprotective and anti-inflammatory approaches. Current data on studies of drugs aimed at symptomatic treatment of MSA are also presented.